Abgenix

About Abgenix

Abgenix is a pioneering biotechnology company based in the United Kingdom, dedicated to advancing the field of therapeutic antibodies. With a strong focus on innovation, we aim to develop cutting-edge treatments for various diseases, including cancer and autoimmune disorders.

Our core activities revolve around the research and development of monoclonal antibodies, which are engineered to target specific antigens in the body. This targeted approach allows for more effective treatments with fewer side effects compared to traditional therapies.

At Abgenix, we believe in the power of collaboration. We work closely with academic institutions, research organisations, and industry partners to leverage the latest scientific advancements and bring new therapies to market.

Our vision is to transform the landscape of medicine by providing patients with access to innovative therapies that improve their quality of life. We are committed to conducting our research ethically and responsibly, ensuring that our developments meet the highest standards of safety and efficacy.

As a company, we value diversity and inclusion, recognising that a diverse workforce drives creativity and innovation. Our team comprises experts from various fields, all united by a common goal: to make a meaningful impact on global health.

In addition to our research efforts, we are also focused on educating healthcare professionals and the public about the potential of antibody therapies. Through outreach and engagement, we aim to raise awareness and understanding of these groundbreaking treatments.

Abgenix is proud to be at the forefront of biopharmaceutical innovation, and we are excited about the future of medicine. Together, we can change lives and create a healthier world.